This hot biotech stock could have a lot more room to run.

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference ("RNAI") ...

When International Institute for Nanotechnology director and chemistry Prof. Chad Mirkin found out last week that he would be the recipient of the 2023-2024 Harvey Prize in Science and Technology, he ...

The University of Toronto has established the Hinton Chair in Artificial Intelligence with $10 million in funding from Google ...

There's a new frontier in treating autoimmune diseases.

A scientist in the French city of Orleans holds up a test tube containing messenger RNA Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

-Nationwide access enabled through FedEx with prepaid shipping both ways.

The exploration of quantum information challenges objective reality, positing the universe as a hologram is explored through ...

Alnylam Pharmaceuticals, Inc. ("Alnylam") , the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain holders of ...

Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director –CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading ...